lactulose has been researched along with Cirrhosis, Liver in 208 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 43 (20.67) | 18.7374 |
| 1990's | 24 (11.54) | 18.2507 |
| 2000's | 27 (12.98) | 29.6817 |
| 2010's | 68 (32.69) | 24.3611 |
| 2020's | 46 (22.12) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, H; Li, J; Liu, H; Qu, L; Yu, A; Zhang, S; Zhao, Y | 1 |
| Choudhuri, G; Goswami, BD; Kalita, P; Kapoor, D; Khaleeq, A; Nijhawan, S; Patil, S; Shah, R | 1 |
| Dalal, A; Jain, A; Kumar, A; Mahajan, B; Sachdeva, S; Sharma, BC; Sonika, U; Srivastava, S | 1 |
| Bashaw, L; Grzyb, K; Louissaint, J; Mohammad, RA; Parikh, ND; Tapper, EB | 1 |
| Giri, S | 1 |
| Gibbs, JT; Louissaint, J; Tapper, EB | 1 |
| Essien, UR; Parikh, ND; Tapper, EB; Ufere, NN; Zhao, Z | 1 |
| Bajaj, JS; Cox, IJ; Escalona-Nandez, I; Fagan, A; Le Guennec, A; McGeorge, S; Peña Rodríguez, M; Rodriguez-Alvarez, F; Rojas-Lara, MV; Torre, A | 1 |
| Gentene, AJ; Guido, M; Pence, A; Stoll, AM | 1 |
| Bajaj, JS; Hassanein, TI; Heimanson, Z; Israel, RJ; Pyrsopoulos, NT; Rahimi, RS; Rockey, DC; Sanyal, AJ | 1 |
| Hayakawa, Y; Higuchi, M; Inada, K; Ishido, S; Izumi, N; Kakegawa, T; Kaneko, S; Kirino, S; Kurosaki, M; Maeyashiki, C; Matsumoto, H; Nakanishi, H; Nobusawa, T; Okamoto, R; Takahashi, Y; Takaura, K; Tamaki, N; Tanaka, S; Tanaka, Y; Tsuchiya, K; Yamashita, K; Yasui, Y | 1 |
| Atkins, AR; Downes, M; Evans, RM; Huan, T; Loomba, R; Madamba, E; Oh, TG; Sharpton, SR; Wang, C; Yu, RT | 1 |
| Chen, W; Feng, X; Jiang, Z; Li, X; Pan, H; Tian, Y; Yang, Q; Yang, Y; Zhang, X | 1 |
| Dugan, AJ; Fritz, MK; Hunt, TV; Karri, K; Mangino, AA; Pitcock, CT; Yarra, P | 1 |
| Faccioli, J; Gioia, S; Nardelli, S; Ridola, L; Riggio, O | 2 |
| Ahmed, Z; Arif, SF; Aziz, M; Badal, J; Farooq, U; Hassan, M; Iqbal, U; Javaid, T; Nawaz, A; Nawras, A; Renno, A; Saab, S; Smith, WL | 1 |
| Djernes, L; Eriksen, PL; Ott, P; Vilstrup, H | 1 |
| Chen, X; Nikirk, S; Ospina, E; Salim, N; Tapper, EB | 1 |
| Chen, KT; Chow, KW; Dang, A; Dang, L; Ibrahim, BM; Jackson, NJ; Saab, S; Yum, JJ | 1 |
| Parikh, ND; Tapper, EB | 1 |
| Li, F; Shi, J | 1 |
| Amodio, P; Shawcross, DL; Thabut, D | 1 |
| Fortune, BE; Jesudian, AB | 1 |
| Anderson, BM; Lewis, DJ; Swansson, WD; Yeoh, SW | 1 |
| Bloom, PP; Tapper, EB | 1 |
| Bajaj, JS; Fagan, A; Nadeem, M; Park, D; Tafader, A; Wade, JB | 1 |
| Brandt, LJ; Feuerstadt, P; Hong, SJ | 1 |
| Bajaj, JS; Guo, XL; Jiang, HX; Meng, LN; Mi, YQ; Shang, J; Wang, BS; Wang, JB; Wang, JY; Xu, JM; Yang, JH; Zhang, NP; Zhou, XM; Zhu, X | 1 |
| Haj, M; Rockey, DC | 1 |
| Borhani, AA; Klinge, MJ; Malik, SM; Neal, M; Varelas, LJ | 1 |
| Adarkwah, CC; Buggisch, P; Frieling, T; Galle, PR; Hofmann, WP; Labenz, C; Labenz, J; Miehlke, S; Wörns, MA | 1 |
| Eder, MD; Hosseini, R; Kravetz, JD; Thomas, A; Varma, P | 1 |
| Ahmad, M; Bozkaya, D; Jesudian, AB; Migliaccio-Walle, K | 1 |
| Bohra, A; Farrell, A; Hui, S; Robertson, M; Terbah, R; Worland, T | 1 |
| Bickett-Burkhart, K; Chalasani, N; Fischer, M; Gandhi, D; Orman, ES; Phatharacharukul, P; Purpura, RD; Xu, H | 1 |
| Bajaj, JS; Fagan, A; Fuchs, M; Gavis, EA; Gillevet, PM; Heuman, DM; Hu, C; Iyer, MV; Iyer, RK; Saboo, K; Shamsaddini, A; Sikaroodi, M; White, MB | 1 |
| Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y | 1 |
| Anjur, V; Bajaj, JS; Biggins, SW; Fallon, MB; Garcia-Tsao, G; Hu, C; Iyer, RK; Kamath, PS; Lai, JC; Maliakkal, B; O'Leary, J; Reddy, KR; Saboo, K; Subramanian, RM; Tandon, P; Thacker, LR; Thuluvath, P; Vargas, H; Wong, F | 1 |
| Bajaj, JS; Bhamidimarri, KR; Bukofzer, S; Potthoff, A; Pyrsopoulos, N; Rahimi, RS; Safadi, R; Thabut, D | 1 |
| Beuers, UHW; Coenen, S; Coenraad, MJ; Cuperus, FJC; de Wit, K; Dijkgraaf, MGW; Kramer, M; Mostafavi, N; Nevens, F; Schaapman, JJ; Takkenberg, RB; Tjwa, ETTL; van Delden, OM; Verbeek, J | 1 |
| Bajaj, JS; Fagan, A; Fuchs, M; Gavis, E; Gillevet, PM; Khoruts, A; Lee, H; Shamsaddini, A; Sikaroodi, M; Sterling, RK | 1 |
| Abu-Zaid, A; Adhami, T; Ayas, MF; Durer, C; Durer, S; Hoilat, GJ; Hoilat, JN; John, S | 1 |
| Chauhan, A; Sharma, S | 1 |
| Akarapatima, K; Chang, A; Chaojin, T; Piratvisuth, T; Rattanasupar, A | 1 |
| López-Sánchez, M; Milke-García, MDP; Moran, S; Rodríguez-Leal, G | 1 |
| Frenette, CT; Levy, C; Saab, S | 1 |
| Flamm, SL | 2 |
| Einstadter, D; Mullen, KD; Pantham, G; Post, A; Venkat, D | 1 |
| De Silva, AP; de Silva, HJ; Gunathilaka, ML; Luke, NV; Niriella, MA; Piyarathna, CL; Siriwardena, RC | 1 |
| Fujimori, N; Ichikawa, Y; Iwaya, M; Iwaya, Y; Joshita, S; Kimura, T; Komatsu, M; Matsumoto, A; Muraki, T; Nakano, H; Shibata, S; Sugiura, A; Tanaka, E; Tanaka, N; Umemura, T; Yamazaki, T | 1 |
| Arias, N; Hadjihambi, A; Jalan, R; Sheikh, M | 1 |
| Baik, SK; Chang, Y; Cho, EJ; Cho, H; Cho, YY; Kang, SH; Kim, MY; Kim, YJ; Lee, JH; Lee, YB; Nam, JY; Yoo, JJ; Yoon, JH; Yu, SJ | 1 |
| Aggarwal, R; Goel, A; Sarangi, AN; Sasi, A; Singh, A | 1 |
| Abd-Elsalam, S; Badawi, R; El-Kalla, F; Elfert, A; Elkhalawany, W; ElSawaf, MA; Elwan, N; Hawash, N; Soliman, S | 1 |
| Choi, BK; Hwang, ES; Kim, HB; Kim, HJ; Kim, JW; Kwon, OI; Kyung, EJ; Lee, S; Lim, SM; Woo, EJ | 1 |
| Abdo-Francis, JM; Alla, SN; Camacho-Aguilera, J; Higuera-de-la-Tijera, F; Jiménez-Ponce, F; Pérez-Hernández, JL; Salas-Gordillo, F; Servín-Caamaño, AI | 1 |
| Horvath, A; Leber, B; Madl, T; Stadlbauer, V; Stryeck, S | 1 |
| Bajaj, JS; Fagan, A; Gavis, EA; Gillevet, PM; Kassam, Z; Sikaroodi, M | 1 |
| Alsahhar, JS; Rahimi, RS | 1 |
| Bracke, B; De Waele, L; Francque, S; Geerinckx, B; Hellemans, R; Kerstens, J; Michielsen, P; Van Craenenbroeck, AH; Van Gaal, PJ; Vanwolleghem, T | 1 |
| Bajaj, JS; Biggins, SW; Fallon, MB; Garcia-Tsao, G; Kamath, PS; Lai, J; Maliakkal, B; O'Leary, JG; Reddy, KR; Subramanian, RM; Tandon, P; Thacker, LR; Thuluvath, PJ; Vargas, HE; Wong, F | 1 |
| Bloom, PP; Chung, RT | 1 |
| Chang, YH; Fang, CJ; Lin, YS; Shen, YC | 1 |
| Jain, L; Puri, SK; Sarin, S; Sharma, BC; Sharma, P; Srivastava, S | 1 |
| Liang, H; Liu, Q; Peng, L; Song, J; Tong, M; Wen, J | 1 |
| Chakraborty, S; Debnath, CR; Debnath, MR; Khan, NA; Nabi, N | 1 |
| Chacko, KR; Sigal, SH | 1 |
| Kanna, S; Mullen, KD; Prakash, RK | 1 |
| Lunia, MK; Sachdeva, S; Sharma, BC; Sharma, P; Srivastava, S | 1 |
| Morillas, RM; Planas, R; Sala, M | 1 |
| Kanna, S; Mullen, K; Waghray, A; Waghray, N | 1 |
| Kutepov, DE; Pasechnik, IN; Sal'nikov, PS; Vershinina, MG | 1 |
| Labenz, J | 1 |
| Cuthbert, JA; Rahimi, RS; Rockey, DC; Singal, AG | 1 |
| Borkar, VV; Kumari, N; Poddar, U; Roy, R; Singh, S; Yachha, SK | 1 |
| Lu, L; Patel, A; Sheasgreen, C | 1 |
| Chawla, R; Jindal, A; Maharshi, S; Sachdeva, S; Sharma, BC; Srivastava, S | 1 |
| Goyal, O; Kishore, H; Parker, RA; Sidhu, SS; Sood, A | 1 |
| Chang, M; Finkelstein, D; Lai, M; Mittleman, MA; Piatkowski, G; Tapper, EB | 1 |
| Alper, TS; Au, J; Saab, EG; Saab, S; Suraweera, D; Tong, MJ | 1 |
| Maharshi, S; Puri, V; Sharma, BC; Singh, J; Srivastava, S | 1 |
| Kliegis, LM; Kropf, S; Malfertheiner, P; Riegger, A; Schmitt, FC; Schulz, C; Schütte, K; Vasapolli, R | 1 |
| Bruns, T; Reuken, PA; Stallmach, A; Stengel, S; Vogt, A | 1 |
| Gluud, LL; Morgan, MY; Vilstrup, H | 1 |
| Ampuero, J; Bellot, P; Figueruela, B; Francés, R; Gallego-Durán, R; González-Navajas, JM; Martínez-Moreno, B; Moratalla, A; Roger, M; Romero-Gómez, M; Such, J; Zapater, P | 1 |
| Colecchia, A; Festi, D; Marasco, G; Ravaioli, F | 1 |
| Bémeur, C; Rombouts, K; Rose, CF | 1 |
| Allampati, S; Bajaj, JS; Fagan, AC; Farcomeni, A; Gavis, EA; Gioia, S; Mullen, KD; Nardelli, S; Prakash, R; Riggio, O; Unser, A; Wade, JB; White, MB | 1 |
| Puri, V; Sachdeva, S; Sharma, BC; Singh, J; Srivastava, S | 1 |
| Agarwalla, A; Davey, S; Goldberg, D; Hamilton, K; Rhim, AD; Weber, A; Yang, YX | 1 |
| Alaei, H; Ghobadi Pour, M; Mirazi, N; Monsef Esfahani, A; Moradkhani, S; Rajaei, Z | 1 |
| Chen, D; Jiang, CY; Wang, BE | 1 |
| Akasaka, HM; de Oliveira Figueiredo, MJ; de Souza Almeida, JR; Lorena, SL; Mesquita, MA; Nagasako, CK; Pavan, CR; Pereira, TS; Soares, EC; Yamanaka, A | 1 |
| Agrawal, A; Sarin, SK; Sharma, BC; Sharma, P | 4 |
| Carbonara, V; Cariello, R; Cartenì, M; Del Vecchio Blanco, C; Esposito, P; Federico, A; Loguercio, C; Martorelli, L; Miranda, A; Palasciano, G; Portincasa, P; Sapone, A; Scialdone, VR; Tiso, A; Tuccillo, C | 1 |
| Sarin, SK; Sharma, BC; Sharma, P | 3 |
| Shaikh, OS; Sundaram, V | 1 |
| Bajaj, JS | 1 |
| Bajaj, JS; Bell, D; Gilles, H; Heuman, DM; Sanyal, AJ | 1 |
| Sharma, P | 1 |
| Bass, NM; Beavers, K; Bortey, E; Forbes, WP; Frederick, T; Hillebrand, D; Huang, S; Leevy, CB; Merchant, K; Mullen, KD; Neff, G; Poordad, F; Sanyal, A; Shaw, A; Sheikh, MY; Sigal, S; Teperman, L | 1 |
| Riordan, SM; Williams, R | 1 |
| Neff, G | 1 |
| Sharma, BC; Sharma, P | 1 |
| Klinken, E; MacQuillan, G | 1 |
| Wakim-Fleming, J | 1 |
| Bajaj, JS; Gillevet, PM; Heuman, DM; Hylemon, PB; Ridlon, JM; Sikaroodi, M; Smith, S; Thacker, LR | 1 |
| Broda, T; Jonas, M; Jones, M; Kaiser, TE; Kemmer, N; Neff, GW; Novick, D; Ravi, R | 1 |
| Abbas, Z; Abid, S; Hamid, S; Islam, M; Jafri, W; Mumtaz, K; Shah, HA | 1 |
| Bajaj, JS; Heuman, DM; Pinkerton, SD; Sanyal, AJ | 1 |
| Fehérvári, I; Gerlei, Z; Görög, D; Kóbori, L; Nemes, B | 1 |
| Jia, JD | 1 |
| Bühner, S; Lochs, H; Norman, K; Pirlich, M; Schulzke, JD; Smoliner, C; Valentini, L | 1 |
| Ferlitsch, A; Hayden, H; Heinisch, BB; Lammert, F; Mandorfer, M; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Trauner, M; Vogelsang, H | 1 |
| Eleftheriadis, D; Eleftheriadis, N; Fourla, E; Karlovasitou, A | 1 |
| Il'chenko, LIu; Petrakov, AV; Shuliat'ev, IS; Sil'verstrova, SIu; Vinnitskaia, EV | 1 |
| Bengmark, S; Hamilton, JA; Kurtovic, J; McCallum, H; McIver, CJ; Nagree, A; Riordan, SM; Skinner, N; Visvanathan, K; Williams, R | 1 |
| Avallone, R; Baraldi, M; Corsi, L; Cosenza, F; Farina, F; Ferrieri, A; Venturini, I; Zeneroli, ML | 1 |
| Gupta, RK; Hasan, KM; Kale, RA; Mishra, AM; Narayana, PA; Pandey, CM; Ranjan, P; Saraswat, VA; Trivedi, R | 1 |
| Leevy, CB; Phillips, JA | 1 |
| Agarwal, R; Chawla, YK; Dhiman, RK; Duseja, A; Prasad, S; Sharma, A | 1 |
| Cho, KJ; Moustafa, T; Semiz-Oysu, A | 1 |
| Gupta, M; Hunter, S; Tumialán, L; Tumialán, LM | 1 |
| Carmassi, F; De Giorgi, A; De Negri, F; Giannarelli, C | 1 |
| Choi, SK; Joo, SY; Kim, HS; Lee, JS; Park, CH; Park, HC; Park, SY; Rew, JS | 1 |
| Cíhalová, J; Dastych, M; Novotná, H | 1 |
| De Marco, F; Giardina, MG; Matarazzo, M; Prantera, T; Verre, C | 1 |
| Blok, IuE; Loginov, AS | 1 |
| Beaven, J; Bjørneklett, A; Blomhoff, JP; Jenssen, E; Skrede, S | 1 |
| Cangiano, C; Cascino, A; De Conciliis, D; Giunchi, G; Merli, M; Riggio, O; Rossi-Fanelli, F; Stortoni, M | 1 |
| Englisch, G; Liehr, H; Rasenack, U | 1 |
| Mörl, M | 1 |
| Müting, D; Reikowski, J; Rosskopf, U | 1 |
| Fukushima, K; Ito, A; Odagiri, S; Tarao, K; Yamazaki, R | 1 |
| Bernardi, R; Fiaccadori, F; Ghinelli, F; Gibertini, P; Pelosi, G; Rocchi, E; Sacchini, D; Santunione, V; Vaona, GL; Ventura, E; Zeneroli, ML | 1 |
| Ferrieri, A; Massimetti, A; Puxeddu, A; Quartini, M | 1 |
| Doffoël, M; Vetter, D | 1 |
| Allaz, JL; Blanc, P; Buttigieg, R; Daurès, JP; Desprez, D; Larrey, D; Liautard, J; Michel, H; Pageaux, G; Parelon, G | 1 |
| Perney, P; Pomier-Layrargues, G | 1 |
| Antezana, C; Chesta, J | 1 |
| Blendis, LM; Fernandes, J; Jenkins, DJ; Koo, M; Morali, G; Rao, AV; Wolever, TM | 1 |
| Kawasaki, H; Murawaki, Y | 1 |
| Kato, M; Moriwaki, H; Murase, M; Muto, Y | 1 |
| Alegría, S; Antezana, C; Chesta, J | 1 |
| Schomerus, H; Schreiegg, J | 1 |
| Abbiati, R; Coltorti, M; Del Vecchio Blanco, C; Loguercio, C; Rinaldi, M; Romano, A | 1 |
| Nolte, W; Ramadori, G | 1 |
| Daenens, C; Desager, JP; Geubel, AP; Horsmans, Y; Solbreux, PM | 1 |
| Bour, AV; Manuk'ian, GV; Shertsinger, AG; Umruzakov, IU | 1 |
| Arakawa, Y; Fujiyama, S; Imai, F; Kawasaki, H; Kobayashi, K; Muto, Y; Ohto, M; Okita, K; Sakai, T; Sato, S; Shimada, S; Tanikawa, K; Toda, G; Tsujii, T; Watanabe, A | 1 |
| Ferenci, P; Miehsler, W; Novacek, G; Penner, E; Vogelsang, H; Wrba, F | 1 |
| Attili, AF; Hassan, C; Meddi, P; Rinaldi, V; Winn, S; Zullo, A | 1 |
| Aussel, C; Bories, PN; Campillo, B; Devanlay, M; Pernet, P; Richardet, JP | 1 |
| Blei, AT | 1 |
| Chawla, YK; Das, G; Dhiman, RK; Dilawari, JB; Ram, S; Sawhney, MS | 1 |
| Blei, AT; Córdoba, J | 1 |
| Goodman, RA; Riley, TR | 1 |
| Holovach, IIu; Mytnyk, ZM; Neĭko, IeM | 1 |
| Dicheva, DT; Iakovenko, EI; Lebedeva, EG; Maev, IV; V'iuchnova, ES | 1 |
| Bettinger, I; Beyer, P; Carley, J; Greenberger, NJ; Schenker, S; Stamnes, C | 1 |
| Demeulenaere, L; van Egmond, J; Van Waes, L | 1 |
| Benzi-Cipelli, R; Bernardi, R; Magliulo, E; Scevola, D; Trpin, L | 1 |
| Bossone, CM | 1 |
| Pusch, JH; Ullmann, W | 1 |
| Imler, M | 2 |
| Schwager, A; Teichmann, W | 1 |
| Müting, D | 3 |
| Thaler, H | 1 |
| Bergonzi, P; Bianco, S; Borzone, A; Butti, A; Cagossi, M; Civello, IM; Nanni, G; Pigliucci, GM | 1 |
| Ferrari, A; Manenti, F | 1 |
| Fischer, R; Müting, D; Ordnung, W | 1 |
| Caschera, M; Diofebi, M; Merli, M; Piat, C; Pinto, G; Riggio, O | 1 |
| Altamura, M; Altomare, E; Cirelli, F; De Vincentiis, A; Palasciano, G; Vendemiale, G | 1 |
| Morgan, MY | 1 |
| Budillon, G; Capocaccia, L; Martino, F; Martorano, M; Merli, M; Parrilli, G; Riggio, O; Romiti, A; Truscelli, A | 1 |
| Ariosto, F; Balducci, G; Capocaccia, L; Merli, M; Riggio, O; Tremiterra, S; Ziparo, V | 1 |
| Candiani, C; Capocaccia, L; Di Rosa, E; Di Rosa, R; Merli, M; Riggio, O; Romiti, A; Testore, GP; Varriale, M | 1 |
| Alonso, M; Morgan, MY; Stanger, LC | 1 |
| Ariosto, F; Balducci, G; Capocaccia, L; Merli, M; Pieche, U; Pinto, G; Riggio, O; Tremiterra, S; Ziparo, V | 1 |
| Heredia, D; Orteu, N; Rodés, J; Terés, J | 1 |
| Hayashi, K; Ikeda, T; Ito, T; Okada, T; Sakurai, A; Tarao, K; Tsuchiya, T | 1 |
| Hawley, KE; Morgan, MY; Stambuk, D | 1 |
| Arroyo, V; Caballería, J; Heredia, D; Ravelli, G; Rodés, J | 1 |
| Maddrey, WC | 1 |
| Budillon, G; Cuomo, R; Menzies, IS; Pacella, M; Parrilli, G | 1 |
| Haerting, J; Mantel, E; Nilius, R; Rink, C | 1 |
| Fischer, JE | 1 |
| Kremer, H | 1 |
| Seidlová, V | 1 |
| Devos, J; Guffens, JM; Pirotte, J | 1 |
| Bell, B; Jacobson, S | 1 |
| Frexinos, J; Germain, L; Louis, A; Ribet, A | 2 |
| Girard, PF; Kopp, N; Trillet, M | 1 |
| Conn, HO; Fessel, JM | 1 |
| Almici, C; Inzoli, MR; Poloni, AE; Zambruni, A | 1 |
42 review(s) available for lactulose and Cirrhosis, Liver
| Article | Year |
|---|---|
Hepatic Encephalopathy in Cirrhotic Patients and Risk of Small Intestinal Bacterial Overgrowth: A Systematic Review and Meta-Analysis.
Topics: Breath Tests; Hepatic Encephalopathy; Humans; Intestine, Small; Lactulose; Liver Cirrhosis | 2022 |
Hepatic encephalopathy - recent advances in treatment and diagnosis.
Topics: Anti-Bacterial Agents; Disaccharides; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Rifaximin | 2023 |
Comparative Efficacy of Treatment Options for the Prevention of Post-TIPS Hepatic Encephalopathy: A Systematic Review and Network Meta-analysis.
Topics: Female; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Network Meta-Analysis; Rifaximin | 2023 |
Diagnosis and Management of Cirrhosis and Its Complications: A Review.
Topics: Adult; Ascites; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; Hepatorenal Syndrome; Humans; Lactulose; Liver Cirrhosis; Liver Neoplasms; Male; Muscle Cramp; Propranolol; Randomized Controlled Trials as Topic; Sodium Potassium Chloride Symporter Inhibitors; Terlipressin; United States | 2023 |
Management of minimal and overt hepatic encephalopathy with branched-chain amino acids: a review of the evidence.
Topics: Amino Acids, Branched-Chain; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Rifaximin | 2023 |
Clinical management of type C hepatic encephalopathy.
Topics: Administration, Oral; Anti-Bacterial Agents; Drug Therapy, Combination; Endovascular Procedures; Enema; Hepatic Encephalopathy; Hepatic Veins; Humans; Imaging, Three-Dimensional; Lactulose; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Portal Vein; Prevalence; Psychometrics; Rifaximin; Severity of Illness Index; Stents; Tomography, X-Ray Computed; Urinary Tract Infections | 2020 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Polyethylene glycol versus lactulose in the treatment of hepatic encephalopathy: a systematic review and meta-analysis.
Topics: Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Polyethylene Glycols | 2021 |
Current approach to treatment of minimal hepatic encephalopathy in patients with liver cirrhosis.
Topics: Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Quality of Life; Rifaximin | 2021 |
Hepatic Encephalopathy-Related Hospitalizations in Cirrhosis: Transition of Care and Closing the Revolving Door.
Topics: Aftercare; Gastrointestinal Agents; Hepatic Encephalopathy; Hospitalization; Humans; Lactulose; Liver Cirrhosis; Patient Discharge; Patient Transfer; Quality of Life; Rifaximin | 2022 |
Hot Topics in Primary Care: Diagnosis of Cirrhosis and Evaluation of Hepatic Encephalopathy: Common Errors and Their Significance for the PCP.
Topics: Anti-Bacterial Agents; Carcinoma, Hepatocellular; Early Detection of Cancer; Education, Medical, Continuing; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Liver Neoplasms; Non-alcoholic Fatty Liver Disease; Practice Guidelines as Topic; Prevalence; Primary Health Care; Risk Factors; United States | 2017 |
Hepatic encephalopathy: a critical current review.
Topics: Albumins; Ammonia; Anti-Bacterial Agents; Bile Acids and Salts; Brain; Brain Edema; Cognitive Dysfunction; Dipeptides; Energy Metabolism; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Ornithine; Portasystemic Shunt, Surgical; Prognosis; Psychometrics; Severity of Illness Index; Synaptic Transmission | 2018 |
Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy.
Topics: Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Rifaximin | 2018 |
Updates on the pathophysiology and therapeutic targets for hepatic encephalopathy.
Topics: Amino Acids, Aromatic; Amino Acids, Branched-Chain; Ammonia; Dipeptides; Fecal Microbiota Transplantation; Frailty; Gastrointestinal Agents; Gastrointestinal Microbiome; Glycerol; Hepatic Encephalopathy; Humans; Hypertension, Portal; Lactulose; Liver Cirrhosis; Ornithine; Phenylbutyrates; Polyethylene Glycols; Probiotics; Rifaximin; Trace Elements; Zinc | 2019 |
A rare case of hemodialysis-related portosystemic encephalopathy and review of the literature.
Topics: Brain; Femoral Vein; Gastrointestinal Agents; Glucocorticoids; Hepatic Encephalopathy; Humans; Kidney Failure, Chronic; Lactulose; Liver Cirrhosis; Magnetic Resonance Imaging; Male; Polycystic Kidney, Autosomal Recessive; Portasystemic Shunt, Transjugular Intrahepatic; Renal Dialysis; Vena Cava, Superior; White Dot Syndromes; Young Adult | 2020 |
Zinc supplementation in patients with cirrhosis and hepatic encephalopathy: a systematic review and meta-analysis.
Topics: Dietary Supplements; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Treatment Outcome; Zinc | 2019 |
Update on management of patients with overt hepatic encephalopathy.
Topics: Disease Management; Drug Therapy, Combination; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Rifamycins; Rifaximin; Secondary Prevention; Severity of Illness Index | 2013 |
Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis.
Topics: Anti-Infective Agents; Clinical Trials as Topic; Gastrointestinal Agents; Gastrointestinal Tract; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Probiotics; Quality of Life; Rifamycins; Rifaximin | 2013 |
[Prevention of hepatic encephalopathy].
Topics: Anti-Bacterial Agents; Central Nervous System Depressants; Contraindications; Diuretics; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; Humans; Hyperammonemia; Intestinal Absorption; Lactulose; Liver Cirrhosis; Liver Transplantation; Meta-Analysis as Topic; Peritonitis; Portasystemic Shunt, Surgical; Postoperative Complications; Recurrence; Rifamycins; Rifaximin; Risk Factors; Sugar Alcohols | 2014 |
Optimal treatment of hepatic encephalopathy.
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Evidence-Based Medicine; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Practice Guidelines as Topic; Probiotics; Quality of Life; Rifamycins; Rifaximin; Severity of Illness Index; Treatment Outcome; United States | 2014 |
[Pay more attention to hepatic encephalopathy].
Topics: Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Long-Term Care; Randomized Controlled Trials as Topic; Rifamycins; Rifaximin; Survival Rate | 2014 |
Pathophysiology, diagnosis, and management of hepatic encephalopathy.
Topics: Ammonia; Anti-Bacterial Agents; Anti-Inflammatory Agents; Hepatic Encephalopathy; Humans; Inflammation; Lactulose; Liver Cirrhosis | 2014 |
Probiotics are helpful in hepatic encephalopathy: a meta-analysis of randomized trials.
Topics: Disease Progression; Hepatic Encephalopathy; Hospitalization; Lactulose; Liver Cirrhosis; Probiotics; Randomized Controlled Trials as Topic | 2016 |
Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.
Topics: Disaccharides; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Neomycin; Randomized Controlled Trials as Topic; Sugar Alcohols; Watchful Waiting | 2016 |
Hepatic encephalopathy: pathophysiology and emerging therapies.
Topics: Ammonia; Anti-Infective Agents; Drug Therapy, Combination; Dyskinesias; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver; Liver Cirrhosis; Liver, Artificial; Manganese; Metronidazole; Neomycin; Neuropsychological Tests; Portasystemic Shunt, Transjugular Intrahepatic; Protein-Energy Malnutrition; Recurrence; Rifamycins; Rifaximin; Trace Elements; Zinc | 2009 |
Review article: the modern management of hepatic encephalopathy.
Topics: Algorithms; Ambulatory Care; Cognition Disorders; Diagnosis, Differential; Disease Progression; Electroencephalography; Event-Related Potentials, P300; Flicker Fusion; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Liver Transplantation; Neuropsychological Tests; Psychometrics; Rifamycins; Rifaximin; Risk Factors; Severity of Illness Index; United States | 2010 |
Minimal hepatic encephalopathy.
Topics: Activities of Daily Living; Attention Deficit Disorder with Hyperactivity; Automobile Driving; Cognition Disorders; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; India; Lactulose; Liver Cirrhosis; Neuropsychological Tests; Prevalence; Psychometrics; Quality of Life; Risk Factors | 2009 |
Factors affecting compliance and persistence with treatment for hepatic encephalopathy.
Topics: Drug Costs; Hepatic Encephalopathy; Hospitalization; Humans; Lactulose; Liver Cirrhosis; Patient Compliance; Rifamycins; Rifaximin | 2010 |
Hepatic encephalopathy: suspect it early in patients with cirrhosis.
Topics: Diagnosis, Differential; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Oxidative Stress; Risk Factors; Severity of Illness Index; Time Factors | 2011 |
[Hepatic encephalopathy and liver transplantation].
Topics: Ammonia; Anti-Infective Agents; Colon; Dipeptides; Disaccharides; End Stage Liver Disease; Evidence-Based Medicine; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Hungary; Hydrogen-Ion Concentration; Lactobacillus; Lactulose; Laxatives; Liver Cirrhosis; Liver Transplantation; Metronidazole; Neomycin; Rifamycins; Rifaximin; Severity of Illness Index; Sugar Alcohols; Systemic Inflammatory Response Syndrome; Treatment Outcome | 2012 |
[Is the "specific" treatment of acute hepatic encephalopathy during liver cirrhosis justified?].
Topics: Acute Disease; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Mannitol; Neomycin; Therapeutic Irrigation | 1994 |
[Hepatic encephalopathy. Physiopathology and treatment].
Topics: Amino Acids; Anti-Bacterial Agents; Drug Therapy, Combination; Flumazenil; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Portacaval Shunt, Surgical | 1994 |
[Pathogenesis and treatment of hepatic encephalopathy].
Topics: Anti-Bacterial Agents; Dietary Proteins; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis | 1994 |
[Therapy of hepatic encephalopathy].
Topics: Acute Disease; Controlled Clinical Trials as Topic; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Recurrence | 1996 |
Brain edema and portal-systemic encephalopathy.
Topics: Brain; Brain Edema; Flumazenil; Glutamine; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Necrosis; Prognosis | 2000 |
[Long-term treatment of chronic hepatitis and liver cirrhosis].
Topics: Adrenal Cortex Hormones; Anabolic Agents; Chronic Disease; Diagnosis, Differential; Diet Therapy; Dietary Fats; Dietary Proteins; Diuretics; Hepatitis; Humans; Immunosuppressive Agents; Lactulose; Liver Cirrhosis; Liver Diseases; Long-Term Care; Penicillamine; Rest; Vitamin B 12 | 1975 |
The treatment of chronic hepatic encephalopathy.
Topics: Amantadine; Amino Acids, Branched-Chain; Anti-Bacterial Agents; Bromocriptine; Dietary Proteins; Hepatic Encephalopathy; Humans; Lactulose; Levodopa; Liver Cirrhosis; Receptors, GABA-A | 1991 |
Branched chain amino acid therapy in liver disease.
Topics: Administration, Oral; Amino Acids; Amino Acids, Branched-Chain; Dietary Proteins; Glucose; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Liver Diseases; Neomycin; Nitrogen; Nutrition Disorders; Parenteral Nutrition | 1985 |
Hepatic coma in cirrhosis, portal hypertension, and following portacaval shunt. Its etiologies and the current status of its treatment.
Topics: Acute Disease; Amino Acids; Ammonia; Brain; Chronic Disease; Colon; Dietary Proteins; Fatty Acids; Glutamine; Hepatic Encephalopathy; Humans; Hypertension, Portal; Lactulose; Liver Cirrhosis; Neomycin; Neurotransmitter Agents; Portacaval Shunt, Surgical; Postoperative Complications; Sterilization; Urease | 1974 |
Recognition and management of acute and chronic hepatic encephalopathy.
Topics: Acute Disease; Amines; Ammonia; Animals; Brain Edema; Central Nervous System; Chronic Disease; Diet Therapy; Dihydroxyphenylalanine; Exchange Transfusion, Whole Blood; Fatty Acids, Volatile; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Neomycin; Renal Dialysis | 1973 |
[Emergency treatment of hepatic coma and porto-caval encephalopathy].
Topics: Acidosis; Alkalosis; Ammonia; Anti-Bacterial Agents; Brain Diseases; Diuretics; Emergencies; Glucose; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis | 1973 |
[Dietary problems in the treatment of portal hypertension with special reference to portacaval shunt].
Topics: Adult; Ammonia; Animals; Diet; Dietary Carbohydrates; Dietary Fats; Dietary Proteins; Humans; Hypertension, Portal; Lactulose; Liver Cirrhosis; Male; Middle Aged; Milk; Phenols; Portacaval Shunt, Surgical; Postoperative Care; Potassium; Sodium; Vitamins | 1974 |
53 trial(s) available for lactulose and Cirrhosis, Liver
| Article | Year |
|---|---|
L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial.
Topics: Ammonia; Aspartic Acid; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Ornithine; Rifaximin; Tumor Necrosis Factor-alpha | 2022 |
Dosing of Rifaximin Soluble Solid Dispersion Tablets in Adults With Cirrhosis: 2 Randomized, Placebo-controlled Trials.
Topics: Adult; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Rifamycins; Rifaximin; Tablets | 2023 |
Clearance and production of ammonia quantified in humans by constant ammonia infusion - the effects of cirrhosis and ammonia-targeting treatments.
Topics: Ammonia; Hepatic Encephalopathy; Humans; Hyperammonemia; Lactulose; Liver Cirrhosis; Male; Phenylbutyrates; Rifaximin | 2023 |
Lactulose therapy for patients with cirrhosis, portal hypertension, and poor patient-reported outcomes: The Mi-Kristal trial.
Topics: Hepatic Encephalopathy; Humans; Hypertension, Portal; Lactulose; Liver Cirrhosis; Middle Aged; Patient Reported Outcome Measures; Quality of Life; Treatment Outcome | 2023 |
Clinical study of probiotics combined with lactulose for minimal hepatic encephalopathy treatment.
Topics: Ammonia; Glycation End Products, Advanced; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Probiotics | 2023 |
Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: A multicenter, randomized controlled trial.
Topics: Adult; Cognition; Female; Gastrointestinal Agents; Gastrointestinal Microbiome; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Quality of Life; Time Factors; Treatment Outcome | 2019 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Efficacy and Safety of Ornithine Phenylacetate for Treating Overt Hepatic Encephalopathy in a Randomized Trial.
Topics: Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Ornithine; Treatment Outcome | 2021 |
Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled t
Topics: Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Portasystemic Shunt, Transjugular Intrahepatic; Quality of Life; Rifaximin | 2020 |
Fecal Microbiota Transplant in Cirrhosis Reduces Gut Microbial Antibiotic Resistance Genes: Analysis of Two Trials.
Topics: Adult; Aged; Anti-Bacterial Agents; Drug Resistance, Microbial; Fecal Microbiota Transplantation; Female; Gastrointestinal Microbiome; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Proton Pump Inhibitors; Rifaximin; Treatment Outcome; Young Adult | 2021 |
Role of lactulose for prophylaxis against hepatic encephalopathy in cirrhotic patients with upper gastrointestinal bleeding: A randomized trial.
Topics: Acute Disease; Gastrointestinal Agents; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Treatment Outcome | 2021 |
A Randomized Controlled Trial Comparing Nitazoxanide Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy.
Topics: Drug Administration Schedule; Drug Therapy, Combination; Female; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Nitro Compounds; Thiazoles; Treatment Outcome | 2019 |
Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding.
Topics: Acute Disease; Adult; Dipeptides; Double-Blind Method; Esophageal and Gastric Varices; Female; Gastrointestinal Agents; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Rifaximin | 2018 |
Long-term Outcomes of Fecal Microbiota Transplantation in Patients With Cirrhosis.
Topics: Anti-Bacterial Agents; Cognition; Fecal Microbiota Transplantation; Follow-Up Studies; Gastrointestinal Agents; Gastrointestinal Microbiome; Hepatic Encephalopathy; Hospitalization; Humans; Lactulose; Liver Cirrhosis; Patient Selection; Rifaximin; Stroop Test; Time Factors | 2019 |
Serum endotoxin, inflammatory mediators, and magnetic resonance spectroscopy before and after treatment in patients with minimal hepatic encephalopathy.
Topics: Adolescent; Adult; Aged; Ammonia; Biomarkers; Endotoxins; Female; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Inflammation Mediators; Interleukin-18; Interleukin-6; Lactulose; Liver Cirrhosis; Magnetic Resonance Spectroscopy; Male; Middle Aged; Tumor Necrosis Factor-alpha; Young Adult | 2013 |
Lactulose is highly potential in prophylaxis of hepatic encephalopathy in patients with cirrhosis and upper gastrointestinal bleeding: results of a controlled randomized trial.
Topics: Adult; Aged; Ammonia; Female; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Treatment Outcome | 2013 |
Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Breath Tests; Female; Glucose; Hepatic Encephalopathy; Humans; India; Lactulose; Liver Cirrhosis; Male; Middle Aged; Probiotics; Prospective Studies; Psychometrics; Severity of Illness Index; Tertiary Care Centers; Treatment Outcome; Young Adult | 2014 |
Lactulose vs polyethylene glycol 3350--electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial.
Topics: Aged; Female; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Surface-Active Agents; Treatment Outcome | 2014 |
Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy.
Topics: Adult; Aged; Cognition; Female; Hepatic Encephalopathy; Humans; India; Lactulose; Liver Cirrhosis; Male; Middle Aged; Neuropsychological Tests; Prospective Studies; Psychometrics; Quality of Life; Rifamycins; Rifaximin; Sickness Impact Profile; Time Factors; Treatment Outcome | 2016 |
RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
Topics: Anti-Infective Agents; Clinical Protocols; Drug Therapy, Combination; Duodenum; Electroencephalography; Endoscopy, Gastrointestinal; Evoked Potentials, Visual; Flicker Fusion; Gastrointestinal Microbiome; Germany; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Pilot Projects; Psychometrics; Research Design; Rifamycins; Rifaximin; Stomach; Time Factors; Treatment Outcome | 2016 |
[Protective effect of compound tongfu granule on intestinal mucosal barrier in patients with cirrhosis of decompensation stage].
Topics: Adult; Aged; Aged, 80 and over; Bifidobacterium; Cell Membrane Permeability; Drugs, Chinese Herbal; Endotoxins; Humans; Intestinal Mucosa; Lactulose; Liver Cirrhosis; Male; Middle Aged; Treatment Outcome | 2008 |
Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo.
Topics: Adult; Female; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Neuropsychological Tests; Psychometrics; Secondary Prevention | 2009 |
Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy.
Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Chronic Disease; Drug Resistance; Female; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Hypertension, Portal; Hyponatremia; Lactulose; Leukocyte Count; Liver Cirrhosis; Liver Failure; Liver Neoplasms; Male; Middle Aged; Predictive Value of Tests; Young Adult | 2010 |
Rifaximin treatment in hepatic encephalopathy.
Topics: Aged; Anti-Infective Agents; Chronic Disease; Clostridioides difficile; Clostridium Infections; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Agents; Hepatic Encephalopathy; Hospitalization; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Lactulose; Liver Cirrhosis; Male; Middle Aged; Proportional Hazards Models; Rifamycins; Rifaximin; Secondary Prevention | 2010 |
Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose.
Topics: Acute Disease; Adult; Blood Transfusion; Chi-Square Distribution; Esophageal and Gastric Varices; Female; Gastrointestinal Agents; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; Humans; India; Lactulose; Liver Cirrhosis; Male; Middle Aged; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2011 |
Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy.
Topics: Anti-Infective Agents; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Agents; Glucose; Hepatic Encephalopathy; Humans; Infusions, Intravenous; Lactulose; Length of Stay; Liver Cirrhosis; Male; Metronidazole; Middle Aged; Prospective Studies; Treatment Outcome | 2011 |
Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose.
Topics: Adult; Chi-Square Distribution; Female; Gastrointestinal Agents; Hepatic Encephalopathy; Hospitalization; Humans; India; Lactulose; Linear Models; Liver Cirrhosis; Male; Middle Aged; Neuropsychological Tests; Primary Prevention; Psychometrics; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2012 |
Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy.
Topics: Adolescent; Adult; Aged; Ammonia; Analysis of Variance; Chi-Square Distribution; Female; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Neuropsychological Tests; Probiotics; Psychometrics; Secondary Prevention; Statistics, Nonparametric; Treatment Outcome | 2012 |
Peripheral blood mononuclear cell expression of toll-like receptors and relation to cytokine levels in cirrhosis.
Topics: Administration, Oral; Adult; Aged; Drosophila Proteins; Endotoxins; Etanercept; Female; Gastrointestinal Agents; Gram-Positive Bacteria; Humans; Immunoglobulin G; In Vitro Techniques; Lactulose; Leukocytes, Mononuclear; Liver Cirrhosis; Male; Membrane Glycoproteins; Middle Aged; Probiotics; Receptors, Cell Surface; Receptors, Tumor Necrosis Factor; Toll-Like Receptor 2; Toll-Like Receptor 4; Toll-Like Receptors; Tumor Necrosis Factor-alpha | 2003 |
Evaluation of rifaximin, placebo and lactulose in reducing the levels of benzodiazepine-like compounds in patients with liver cirrhosis: a pilot study.
Topics: Adult; Aged; Benzodiazepines; Chromatography, High Pressure Liquid; Drug Evaluation; Female; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Pilot Projects; Placebos; Rifamycins; Rifaximin | 2005 |
Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy.
Topics: Activities of Daily Living; Adult; Aged; Cognition; Female; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Neuropsychological Tests; Psychometrics; Psychomotor Performance; Quality of Life; Sickness Impact Profile | 2007 |
Branched-chain amino acids vs lactulose in the treatment of hepatic coma: a controlled study.
Topics: Amino Acids; Amino Acids, Branched-Chain; Ammonia; Clinical Trials as Topic; Disaccharides; Glucose; Hepatic Encephalopathy; Humans; Infusions, Parenteral; Lactulose; Liver Cirrhosis | 1982 |
Rifaximin in the treatment of chronic hepatic encephalopathy.
Topics: Adult; Aged; Aged, 80 and over; Ammonia; Analysis of Variance; Anti-Bacterial Agents; Chronic Disease; Drug Synergism; Drug Therapy, Combination; Electroencephalography; Female; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Movement Disorders; Psychiatric Status Rating Scales; Rifamycins; Rifaximin; Time Factors; Treatment Outcome | 1995 |
[Lactulose-neomycin combination versus placebo in the treatment of acute hepatic encephalopathy. Results of a randomized controlled trial].
Topics: Acute Disease; Aged; Drug Therapy, Combination; Female; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Neomycin; Placebos | 1994 |
[Effects of neomycin on intestinal digestion, absorption and fermentation of carbohydrates in patients with liver cirrhosis: evidence for an alternative therapeutic mechanism in hepatic encephalopathy].
Topics: Carbohydrate Metabolism; Digestion; Female; Fermentation; Hepatic Encephalopathy; Humans; Intestinal Absorption; Lactose; Lactulose; Liver Cirrhosis; Male; Middle Aged; Neomycin; Time Factors; Xylose | 1994 |
Effect of acute lactulose administration on serum acetate levels in cirrhosis.
Topics: Acetates; Adult; Aged; Ammonia; Blood Glucose; Colon; Cross-Over Studies; Diet; Fatty Acids, Nonesterified; Female; Fermentation; Humans; Hydrogen; Insulin; Lactulose; Liver Cirrhosis; Male; Middle Aged; Respiration | 1994 |
Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy.
Topics: Adult; Aged; Ammonia; Dose-Response Relationship, Drug; Double-Blind Method; Enterococcus faecium; Evoked Potentials, Visual; Female; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Severity of Illness Index; Time Factors | 1995 |
Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy.
Topics: Female; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Psychiatric Status Rating Scales | 1997 |
Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy.
Topics: Administration, Oral; Adult; Aged; Ammonia; Cathartics; Female; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Wechsler Scales | 1997 |
Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy.
Topics: Adult; Female; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Psychological Tests; Treatment Outcome | 2000 |
[The response to combined therapy of hepatic encephalopathy in patients with hepatic cirrhosis].
Topics: Adult; Dipeptides; Drug Therapy, Combination; Female; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged | 2002 |
Effect of vegetable and animal protein diets in chronic hepatic encephalopathy.
Topics: Adult; Amino Acids; Chronic Disease; Clinical Trials as Topic; Dietary Proteins; Female; Hepatic Encephalopathy; Humans; Intelligence Tests; Lactulose; Liver Cirrhosis; Liver Function Tests; Male; Meat; Methionine; Middle Aged; Plant Proteins, Dietary; Proteins | 1977 |
The effect of lactulose and lactitol administration on fecal fat excretion in patients with liver cirrhosis.
Topics: Adult; Aged; Feces; Hepatic Encephalopathy; Humans; Intestinal Absorption; Lactulose; Lipid Metabolism; Liver Cirrhosis; Male; Middle Aged; Sugar Alcohols | 1992 |
Crystalline lactulose in the therapy of hepatic cirrhosis. Evaluation of clinical and immunological parameters. Preliminary results.
Topics: Adult; Aged; Ammonia; Bilirubin; Blood Bactericidal Activity; Crystallization; Female; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Suspensions | 1992 |
Lactitol in the treatment of chronic hepatic encephalopathy--a randomized cross-over comparison with lactulose.
Topics: Adult; Aged; Chronic Disease; Female; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Portasystemic Shunt, Surgical; Sugar Alcohols | 1990 |
Effect of lactitol and lactulose administration on the fecal flora in cirrhotic patients.
Topics: Animals; Bifidobacterium; Clostridium; Coccidia; Disaccharides; Enterobacteriaceae; Feces; Humans; Hydrogen-Ion Concentration; Lactobacillus; Lactulose; Liver Cirrhosis; Sugar Alcohols | 1990 |
Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. A randomised, cross-over study.
Topics: Clinical Trials as Topic; Disaccharides; Electroencephalography; Female; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Psychological Tests; Random Allocation; Sugar Alcohols | 1989 |
Lactitol in prevention of recurrent episodes of hepatic encephalopathy in cirrhotic patients with portal-systemic shunt.
Topics: Adolescent; Adult; Amino Acids; Clinical Trials as Topic; Female; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Portasystemic Shunt, Surgical; Random Allocation; Recurrence; Sugar Alcohols | 1989 |
Lactitol vs. lactulose in the treatment of chronic recurrent portal-systemic encephalopathy.
Topics: Clinical Trials as Topic; Disaccharides; Female; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Male; Middle Aged; Neuropsychological Tests; Recurrence; Sugar Alcohols | 1988 |
Lactitol versus lactulose in the treatment of chronic hepatic encephalopathy. A double-blind, randomised, cross-over study.
Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Disaccharides; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Random Allocation; Sugar Alcohols | 1987 |
Lactitol versus lactulose in the treatment of acute portal systemic encephalopathy (PSE). A controlled trial.
Topics: Acute Disease; Adult; Aged; Bacterial Infections; Disaccharides; Electroencephalography; Female; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Sugar Alcohols | 1987 |
[Double blind study of lactulose in 8 patients with chronic hepatic encephalopathy after portocaval shunt].
Topics: Adult; Aged; Ammonia; Brain Diseases; Chronic Disease; Clinical Trials as Topic; Disaccharides; Electroencephalography; Female; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Neurologic Manifestations; Placebos; Portacaval Shunt, Surgical | 1973 |
[Double blind study of lactulose in 8 patients with chronic hepatic encephalopathy after portocaval shunt].
Topics: Adult; Aged; Ammonia; Brain Diseases; Chronic Disease; Clinical Trials as Topic; Disaccharides; Electroencephalography; Female; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Neurologic Manifestations; Placebos; Portacaval Shunt, Surgical | 1973 |
114 other study(ies) available for lactulose and Cirrhosis, Liver
| Article | Year |
|---|---|
Studies on intestinal permeability of cirrhotic patients by analysis lactulose and mannitol in urine with HPLC/RID/MS.
Topics: Chromatography, High Pressure Liquid; Humans; Intestinal Absorption; Lactulose; Liver Cirrhosis; Mannitol; Permeability; Refractometry; Spectrometry, Mass, Electrospray Ionization | 2004 |
Primary Prophylaxis Patterns for Hepatic Encephalopathy in Patients with Liver Cirrhosis: What are the Current Prescribing Trends in Specialty Practice?
Topics: Cross-Sectional Studies; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis | 2021 |
An Electronic Decision Support Intervention Reduces Readmissions for Patients With Cirrhosis.
Topics: Drug Therapy, Combination; Electronics; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Patient Readmission; Rifaximin | 2022 |
Polyethylene Glycol Versus Lactulose for Hepatic Encephalopathy: Do We Have a Clear Winner?
Topics: Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Polyethylene Glycols | 2022 |
Rate of Successful Extubation in Mechanically Ventilated Patients with Cirrhosis and Hepatic Coma.
Topics: Airway Extubation; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Prospective Studies; Respiration, Artificial; Respiratory Insufficiency; Retrospective Studies; Rifaximin | 2022 |
Racial and ethnic disparities in rifaximin use and subspecialty referrals for patients with hepatic encephalopathy in the United States.
Topics: Aged; Ethnicity; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Medicare; Referral and Consultation; Rifaximin; United States | 2022 |
Stool microbiota show greater linkages with plasma metabolites compared to salivary microbiota in a multinational cirrhosis cohort.
Topics: Feces; Humans; Lactates; Lactulose; Liver Cirrhosis; Microbiota; RNA, Ribosomal, 16S | 2022 |
Lack of Access to Rifaximin Upon Hospital Discharge Is Frequent and Results in Increased Hospitalizations for Hepatic Encephalopathy.
Topics: Drug Therapy, Combination; Gastrointestinal Agents; Hepatic Encephalopathy; Hospitalization; Hospitals; Humans; Lactulose; Liver Cirrhosis; Patient Discharge; Retrospective Studies; Rifamycins; Rifaximin | 2023 |
Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy.
Topics: Ammonia; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Rifamycins; Rifaximin | 2023 |
Gut metagenome-derived signature predicts hepatic decompensation and mortality in NAFLD-related cirrhosis.
Topics: Adult; Ascites; End Stage Liver Disease; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Metagenome; Non-alcoholic Fatty Liver Disease; Prospective Studies; Rifaximin; Severity of Illness Index | 2022 |
Clinical Outcomes of Oral Zinc Therapy in Hepatic Encephalopathy Treatment.
Topics: Drug Therapy, Combination; End Stage Liver Disease; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Retrospective Studies; Rifamycins; Rifaximin; Severity of Illness Index; Zinc | 2023 |
Barriers to Lactulose Adherence in Patients with Cirrhosis and Hepatic Encephalopathy.
Topics: Gastrointestinal Agents; Hepatic Encephalopathy; Hospitalization; Humans; Lactulose; Liver Cirrhosis | 2023 |
Ammonia - an enduring foe - What evaluating whole body ammonia metabolism can teach us about cirrhosis and therapies treating hepatic encephalopathy.
Topics: Ammonia; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Rifamycins; Rifaximin | 2023 |
The PROs and cons of crystalline lactulose for suspected covert HE among patients with cirrhosis and activity impairment: Are we using the right assessments?
Topics: Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis | 2023 |
Lactulose in cirrhosis: Current understanding of efficacy, mechanism, and practical considerations.
Topics: Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Quality of Life | 2023 |
A specialized HE testing clinic improves rational decision-making for therapy in cirrhosis.
Topics: End Stage Liver Disease; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Severity of Illness Index; Sleep Apnea, Obstructive | 2023 |
Chronic Rifaximin Use in Cirrhotic Patients Is Associated with Decreased Rate of C. difficile Infection.
Topics: Aged; Anti-Bacterial Agents; Chemoprevention; Clostridioides difficile; Clostridium Infections; Diarrhea; End Stage Liver Disease; Female; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Intensive Care Units; Lactulose; Liver Cirrhosis; Male; Middle Aged; Mortality; Retrospective Studies; Rifaximin; Severity of Illness Index | 2020 |
Ammonia Levels Do Not Guide Clinical Management of Patients With Hepatic Encephalopathy Caused by Cirrhosis.
Topics: Ammonia; Biomarkers; Disease Management; Female; Follow-Up Studies; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Inpatients; Lactulose; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2020 |
Idiopathic pneumatosis intestinalis secondary to lactulose use in patients with cirrhosis.
Topics: Aged; Cohort Studies; Female; Gastrointestinal Agents; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Pneumatosis Cystoides Intestinalis | 2020 |
Management of hepatic encephalopathy in Germany: a survey among physicians.
Topics: Disease Management; Gastroenterologists; Gastrointestinal Agents; General Practitioners; Germany; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Practice Patterns, Physicians'; Quality of Life; Rifaximin; Secondary Prevention; Surveys and Questionnaires | 2020 |
A Confusing Picture: Refractory Encephalopathy Complicating Nonalcoholic Steatohepatitis.
Topics: Aged; Brain; Confusion; Dyskinesias; Esophageal and Gastric Varices; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Hyperammonemia; Hyperbilirubinemia; Hypertension, Portal; Lactulose; Liver Cirrhosis; Magnetic Resonance Imaging; Male; Non-alcoholic Fatty Liver Disease; Renal Veins; Rifaximin; Splenic Vein; Thrombocytopenia; Tomography, X-Ray Computed; Tremor; Vascular Diseases | 2020 |
Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy.
Topics: Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Hepatic Encephalopathy; Hospitalization; Humans; Incidence; Lactulose; Liver Cirrhosis; Liver Transplantation; Maintenance Chemotherapy; Markov Chains; Models, Economic; Quality of Life; Quality-Adjusted Life Years; Recurrence; Rifaximin; Secondary Prevention | 2020 |
Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care.
Topics: Aged; Clinical Decision-Making; Female; Follow-Up Studies; Hepatic Encephalopathy; Humans; Kaplan-Meier Estimate; Lactulose; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Patient Selection; Prognosis; Retrospective Studies; Rifaximin; Severity of Illness Index; Standard of Care; Treatment Outcome | 2020 |
Incidence and Risk Factors of Recurrent Clostridioides difficile Infection in Patients With Cirrhosis.
Topics: Aged; Anti-Bacterial Agents; Clostridioides; Clostridium Infections; Comorbidity; Diagnostic Errors; Female; Fidaxomicin; Humans; Incidence; Lactulose; Laxatives; Liver Cirrhosis; Male; Metronidazole; Middle Aged; Patient Readmission; Recurrence; Retrospective Studies; Risk Factors; Severity of Illness Index; Treatment Failure; Vancomycin | 2020 |
Sex is associated with differences in gut microbial composition and function in hepatic encephalopathy.
Topics: Brain-Gut Axis; Correlation of Data; Cross-Sectional Studies; End Stage Liver Disease; Female; Gastrointestinal Agents; Gastrointestinal Microbiome; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Rifaximin; RNA, Ribosomal, 16S; Sequence Analysis, RNA; Sex Factors | 2021 |
Low Predictability of Readmissions and Death Using Machine Learning in Cirrhosis.
Topics: Adrenergic beta-Antagonists; Aged; Anti-Bacterial Agents; Ascites; beta-Lactams; Clinical Decision Rules; Cohort Studies; End Stage Liver Disease; Female; Gastrointestinal Agents; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; Humans; Hydrothorax; Infections; Kidney Diseases; Lactulose; Liver Cirrhosis; Logistic Models; Machine Learning; Male; Middle Aged; Mortality; Paracentesis; Patient Readmission; Proton Pump Inhibitors; Reproducibility of Results; Rifaximin; ROC Curve; Severity of Illness Index; Support Vector Machine; Water-Electrolyte Imbalance | 2021 |
Use of Lactulose in Hepatic Encephalopathy: Is It Time to Shift Targets?
Topics: Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis | 2022 |
A New Look at Precipitants of Overt Hepatic Encephalopathy in Cirrhosis.
Topics: Acute Kidney Injury; Constipation; Dehydration; Female; Gastrointestinal Agents; Hepatic Encephalopathy; Hospitalization; Humans; Lactulose; Liver Cirrhosis; Male; Medication Adherence; Middle Aged; Prospective Studies; Retrospective Studies; Safety-net Providers; Severity of Illness Index | 2017 |
Possible gasoline-induced chronic liver injury due to occupational malpractice in a motor mechanic: a case report.
Topics: Automobiles; Cholagogues and Choleretics; Directive Counseling; Diuretics; Furosemide; Gasoline; Gastrointestinal Agents; Hepatomegaly; Humans; Hydrocarbons; Lactulose; Liver Cirrhosis; Male; Malpractice; Occupational Diseases; Occupational Exposure; Spironolactone; Treatment Outcome; Ursodeoxycholic Acid; Young Adult | 2017 |
Cimetidine/lactulose therapy ameliorates erythropoietic protoporphyria-related liver injury.
Topics: 5-Aminolevulinate Synthetase; Cimetidine; Gastrointestinal Agents; Humans; Lactulose; Liver; Liver Cirrhosis; Male; Protoporphyria, Erythropoietic; Protoporphyrins; Young Adult | 2017 |
Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy.
Topics: Aged; Anti-Infective Agents; Bacterial Infections; Carcinoma, Hepatocellular; Esophageal and Gastric Varices; Female; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Peritonitis; Recurrence; Retrospective Studies; Rifamycins; Rifaximin; Secondary Prevention | 2017 |
Faecal bacterial microbiota in patients with cirrhosis and the effect of lactulose administration.
Topics: Adult; Aged; Feces; Female; Gastrointestinal Agents; Gastrointestinal Microbiome; High-Throughput Nucleotide Sequencing; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; RNA, Ribosomal, 16S | 2017 |
Evaluation of Hepatoprotective Effect of Curcumin on Liver Cirrhosis Using a Combination of Biochemical Analysis and Magnetic Resonance-Based Electrical Conductivity Imaging.
Topics: Animals; Anti-Inflammatory Agents; Curcumin; Dimethylnitrosamine; Electric Conductivity; Lactulose; Liver; Liver Cirrhosis; Rats; Rats, Sprague-Dawley | 2018 |
NMR spectroscopy enables simultaneous quantification of carbohydrates for diagnosis of intestinal and gastric permeability.
Topics: Adult; Female; Gastric Mucosa; Healthy Volunteers; Humans; Intestinal Mucosa; Lactulose; Liver Cirrhosis; Magnetic Resonance Spectroscopy; Male; Permeability; Prospective Studies; Reproducibility of Results; Sucrose; Time Factors; Young Adult | 2018 |
Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort.
Topics: Aged; Cohort Studies; Drug Therapy, Combination; End Stage Liver Disease; Female; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Quality of Health Care; Recurrence; Rifaximin | 2019 |
Editorial: mind the gaps - an important first step towards improving hepatic encephalopathy care.
Topics: Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis | 2019 |
A case of Gaucher's disease progressing to liver cirrhosis.
Topics: Adolescent; Anti-Bacterial Agents; Cefuroxime; Diagnosis, Differential; Disease Progression; Female; Gaucher Disease; Humans; Lactulose; Liver Cirrhosis; Vitamins | 2013 |
[Comparative effectiveness of different treatment methods of liver failure].
Topics: Comparative Effectiveness Research; Dipeptides; Extracorporeal Circulation; Female; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Liver Failure; Male; Middle Aged; Monitoring, Physiologic; Plasma Exchange; Sorption Detoxification; Treatment Outcome | 2014 |
Duodenal morphometry and small bowel permeability in children with portal hypertension.
Topics: Adolescent; Biopsy; Body Height; Body Weight; Case-Control Studies; Child; Constriction, Pathologic; Dietary Proteins; Duodenal Diseases; Duodenum; Energy Intake; Humans; Hypertension, Portal; Lactulose; Liver Cirrhosis; Mannitol; Nutritional Status; Permeability; Portal Vein; Prospective Studies; Skinfold Thickness; Vascular Diseases; Young Adult | 2015 |
Bispectral index monitoring for diagnosis and assessment of severity of hepatic encephalopathy in cirrhotic patients.
Topics: Adult; Ammonia; Case-Control Studies; Female; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Neuropsychological Tests; Prospective Studies; Psychometrics; ROC Curve; Severity of Illness Index | 2015 |
A Quality Improvement Initiative Reduces 30-Day Rate of Readmission for Patients With Cirrhosis.
Topics: Adult; Aged; Antibiotic Prophylaxis; Female; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Patient Readmission; Prospective Studies; Quality Improvement; Rifamycins; Rifaximin; Treatment Outcome | 2016 |
Spectral electroencephalogram in liver cirrhosis with minimal hepatic encephalopathy before and after lactulose therapy.
Topics: Adult; Brain; Case-Control Studies; Electroencephalography; Female; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Neuropsychological Tests; Predictive Value of Tests; Psychometrics; Remission Induction; Reproducibility of Results; Severity of Illness Index; Time Factors; Treatment Outcome | 2016 |
Dual-sugar tests of small intestinal permeability are poor predictors of bacterial infections and mortality in cirrhosis: A prospective study.
Topics: Adult; Aged; Aged, 80 and over; Bacterial Infections; Bacterial Translocation; Case-Control Studies; Disease-Free Survival; Female; Gastrointestinal Microbiome; Hospitalization; Humans; Inflammation Mediators; Intestine, Small; Kaplan-Meier Estimate; Lactulose; Linear Models; Liver Cirrhosis; Male; Mannitol; Middle Aged; Peritonitis; Permeability; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prospective Studies; Risk Factors; Time Factors | 2016 |
Lactulose reduces bacterial DNA translocation, which worsens neurocognitive shape in cirrhotic patients with minimal hepatic encephalopathy.
Topics: Aged; Ammonia; Bacterial Translocation; Biomarkers; Cognition; DNA, Bacterial; Female; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Psychometrics; Severity of Illness Index; Spain | 2017 |
[Hepatic encephalopathy].
Topics: Anti-Bacterial Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Treatment Outcome | 2016 |
Targeting the muscle for the treatment and prevention of hepatic encephalopathy.
Topics: Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Muscles | 2016 |
Hepatic Encephalopathy Is Associated with Persistent Learning Impairments Despite Adequate Medical Treatment: A Multicenter, International Study.
Topics: Aged; Cognition; Female; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Intelligence Tests; Italy; Lactulose; Learning Disabilities; Liver Cirrhosis; Male; Mental Competency; Middle Aged; Psychometrics; United States | 2017 |
Sleep disturbances in patients of liver cirrhosis with minimal hepatic encephalopathy before and after lactulose therapy.
Topics: Adult; Ammonia; Disorders of Excessive Somnolence; Female; Flicker Fusion; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Neuropsychological Tests; Polysomnography; Psychometrics; Quality of Life; Sleep Wake Disorders; Treatment Outcome | 2017 |
Lactulose Is Associated With Decreased Risk of Clostridium difficile Infection in Decompensated Cirrhosis.
Topics: Aged; Case-Control Studies; Clostridium Infections; Female; Gastrointestinal Agents; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Prebiotics | 2017 |
Effects of lactulose and silymarin on liver enzymes in cirrhotic rats.
Topics: Animals; Drug Interactions; Lactulose; Lipid Peroxidation; Liver; Liver Cirrhosis; Male; Rats; Rats, Wistar; Silymarin; Thioacetamide | 2017 |
Investigation of autonomic function and orocecal transit time in patients with nonalcoholic cirrhosis and the potential influence of these factors on disease outcome.
Topics: Adult; Autonomic Nervous System; Breath Tests; Disease Progression; Electrocardiography, Ambulatory; Female; Gastrointestinal Transit; Heart Rate; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Prognosis; Severity of Illness Index; Time Factors | 2009 |
Intestinal permeability in patients with chronic liver diseases: Its relationship with the aetiology and the entity of liver damage.
Topics: Adult; Age Factors; Aged; Alcoholism; Case-Control Studies; Diabetes Complications; Female; Hepatitis, Chronic; Humans; Hypertension, Portal; Interleukin-6; Intestinal Absorption; Lactulose; Liver Cirrhosis; Male; Mannitol; Middle Aged; Nitrites; S-Nitrosothiols; Tumor Necrosis Factor-alpha | 2010 |
Predictors of nonresponse to lactulose for minimal hepatic encephalopathy in patients with cirrhosis.
Topics: Adult; Ammonia; Event-Related Potentials, P300; Female; Flicker Fusion; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Psychometrics; Sodium | 2009 |
Critical flicker frequency for diagnosis and assessment of recovery from minimal hepatic encephalopathy in patients with cirrhosis.
Topics: Adult; Case-Control Studies; Event-Related Potentials, P300; Female; Flicker Fusion; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Psychometrics; Recovery of Function | 2010 |
Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Patient Compliance; Recurrence; Retrospective Studies; Young Adult | 2010 |
Gut flora and hepatic encephalopathy in patients with cirrhosis.
Topics: Ammonia; Anti-Infective Agents; Gastrointestinal Agents; Gastrointestinal Tract; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Rifamycins; Rifaximin; Secondary Prevention | 2010 |
Rifaximin treatment in hepatic encephalopathy.
Topics: Anti-Infective Agents; Gastrointestinal Agents; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Peritonitis; Rifamycins; Rifaximin | 2010 |
Lactulose a day keeps encephalopathy at bay.
Topics: Acute Disease; Blood Transfusion; Esophageal and Gastric Varices; Gastrointestinal Agents; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2011 |
Linkage of gut microbiome with cognition in hepatic encephalopathy.
Topics: Cognition Disorders; Cytokines; Endotoxins; Feces; Female; Gastrointestinal Agents; Gastrointestinal Tract; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Metagenome; Middle Aged; Rifamycins; Rifaximin; Systems Biology | 2012 |
Durability of rifaximin response in hepatic encephalopathy.
Topics: Adult; Aged; Anti-Infective Agents; Drug Therapy, Combination; End Stage Liver Disease; Female; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Rifamycins; Rifaximin; Severity of Illness Index; Time Factors | 2012 |
Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis.
Topics: Accidents, Traffic; Aged; Cohort Studies; Cost-Benefit Analysis; Follow-Up Studies; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Markov Chains; Middle Aged; Neuropsychological Tests; Psychometrics; Rifamycins; Rifaximin; Severity of Illness Index; United States | 2012 |
Lactulose in the treatment of hepatic encephalopathy: new evidence for an old modality.
Topics: Female; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Primary Prevention | 2012 |
Increased intestinal permeability in malnourished patients with liver cirrhosis.
Topics: Aged; Atrophy; Dietary Sucrose; Female; Gastric Mucosa; Gastrointestinal Tract; Humans; Intestinal Mucosa; Lactulose; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Male; Malnutrition; Mannitol; Middle Aged; Nutrition Assessment; Organ Specificity; Permeability; Severity of Illness Index | 2012 |
Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis.
Topics: Acute-Phase Proteins; Adrenergic beta-Antagonists; Adult; Aged; Bacterial Translocation; Carrier Proteins; Cell Membrane Permeability; Comorbidity; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Portal; Interleukin-6; Intestinal Absorption; Kaplan-Meier Estimate; Lactulose; Liver Cirrhosis; Male; Mannitol; Membrane Glycoproteins; Middle Aged; Sucrose | 2013 |
Status epilepticus as a manifestation of hepatic encephalopathy.
Topics: Acidosis; Anticonvulsants; Electroencephalography; Female; Hepatic Encephalopathy; Hepatitis B; Humans; Hyperammonemia; Hypoxia; Lactulose; Liver Cirrhosis; Middle Aged; Status Epilepticus | 2003 |
[Lactulose in treatment of hepatic encephalopathy in patient with liver cirrhosis].
Topics: Adult; Aged; Female; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Quality of Life | 2002 |
[Cirrhotic liver gives up in breaking up of ammonia. Poison for the brain].
Topics: Ammonia; Clinical Trials as Topic; Dipeptides; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Quality of Life; Self-Help Groups | 2004 |
Demonstration of interstitial cerebral edema with diffusion tensor MR imaging in type C hepatic encephalopathy.
Topics: Adolescent; Adult; Anisotropy; Brain; Brain Edema; Case-Control Studies; Diffusion Magnetic Resonance Imaging; Female; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Neuropsychological Tests; Treatment Outcome | 2006 |
Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy.
Topics: Adult; Female; Gastrointestinal Agents; Hepatic Encephalopathy; Hospitalization; Humans; Lactulose; Length of Stay; Liver Cirrhosis; Male; Middle Aged; New Jersey; Rifamycins; Rifaximin | 2007 |
Transjugular intrahepatic portosystemic shunt prior to cardiac surgery with cardiopulmonary bypass in patients with cirrhosis and portal hypertension.
Topics: Aged; Aortic Valve Stenosis; Cardiac Tamponade; Cardiopulmonary Bypass; Coronary Artery Disease; Gastrointestinal Agents; Hepatic Encephalopathy; Humans; Hypertension, Portal; Lactulose; Liver Cirrhosis; Male; Middle Aged; Portasystemic Shunt, Transjugular Intrahepatic; Postoperative Hemorrhage | 2007 |
A 55-year-old man with liver failure, delirium and seizures.
Topics: Brain; Delirium; Diagnosis, Differential; Fatal Outcome; Gastrointestinal Agents; Granuloma, Giant Cell; Hepatic Encephalopathy; Humans; Kidney; Lactulose; Liver; Liver Cirrhosis; Liver Failure, Acute; Lymph Nodes; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Middle Aged; Multiple Organ Failure; Sarcoidosis; Seizures | 2007 |
Decompensated porto-pulmonary hypertension in a cirrhotic patient with thrombosis of portocaval shunt.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diet, Sodium-Restricted; Diuretics; Drug Therapy, Combination; Dyspnea; Edema; Female; Fibrinolytic Agents; Gastrointestinal Agents; Heparin, Low-Molecular-Weight; Humans; Hypertension, Portal; Hypertension, Pulmonary; Lactulose; Liver Cirrhosis; Portal Pressure; Portasystemic Shunt, Surgical; Spironolactone; Treatment Outcome; Vasodilator Agents; Venous Thrombosis | 2007 |
[A case of pneumatosis cystoides intestinalis in a cirrhosis patient].
Topics: Gastrointestinal Agents; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Pneumatosis Cystoides Intestinalis; Tomography, X-Ray Computed | 2007 |
Lactulose/mannitol test and specificity, sensitivity, and area under curve of intestinal permeability parameters in patients with liver cirrhosis and Crohn's disease.
Topics: Adult; Aged; Area Under Curve; Case-Control Studies; Cell Membrane Permeability; Creatinine; Crohn Disease; Diagnostic Tests, Routine; Female; Humans; Intestinal Absorption; Lactulose; Liver Cirrhosis; Male; Mannitol; Middle Aged; Sensitivity and Specificity | 2008 |
[Plasma amino acids in patients with liver cirrhosis treated with lactulose].
Topics: Adult; Aged; Amino Acids; Amino Acids, Branched-Chain; Disaccharides; Female; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged | 1984 |
[Diagnosis and treatment of hyperazotemia in liver cirrhosis].
Topics: Ammonia; Drug Therapy, Combination; Female; Humans; Lactulose; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Ornithine; Uremia | 1983 |
Pulmonary hydrogen and methane and plasma ammonia after the administration of lactulose or sorbitol.
Topics: Adult; Ammonia; Breath Tests; Disaccharides; Female; Fermentation; Humans; Hydrogen; Intestinal Mucosa; Intestines; Lactulose; Liver Cirrhosis; Male; Methane; Middle Aged; Sorbitol | 1983 |
Lactulose--a drug with antiendotoxin effect.
Topics: Animals; Antitoxins; Chemical and Drug Induced Liver Injury; Culture Techniques; Disaccharides; Endotoxins; Escherichia coli; Galactosamine; Lactulose; Limulus Test; Liver; Liver Cirrhosis; Rats; Toxemia | 1980 |
[Main characteristics of the treatment of liver cirrhosis].
Topics: Adolescent; Adult; Ascites; Bed Rest; Bloodletting; Child; Child, Preschool; Cholestyramine Resin; Dietary Fats; Dietary Proteins; Diuretics; Energy Intake; Female; Hemochromatosis; Hepatic Encephalopathy; Hepatolenticular Degeneration; Humans; Lactulose; Liver Cirrhosis; Liver Cirrhosis, Biliary; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Penicillamine; Potassium; Vitamin B 12 | 1981 |
[Bifidum-milk and lactulose in the therapy of chronic liver diseases].
Topics: Ammonia; Child; Disaccharides; Female; Humans; Lactobacillus; Lactulose; Liver Cirrhosis; Liver Diseases; Phenols | 1980 |
[Faecal bacterial flora in cirrhotic patients and effects of administration of antibiotics or lactulose (author's transl)].
Topics: Anti-Bacterial Agents; Bacteria; Disaccharides; Feces; Humans; Lactulose; Liver Cirrhosis; Minocycline; Neomycin; Paromomycin | 1980 |
[Preliminary observations and indications in the use of selective amino acid solutions in cirrhosis encephalopathy].
Topics: Adult; Aged; Amino Acids; Brain Diseases, Metabolic; Electroencephalography; Humans; Lactulose; Liver Cirrhosis; Middle Aged | 1980 |
[Recent advances in the treatment of decompensated liver cirrhosis].
Topics: Albumins; Alprostadil; Amino Acids, Branched-Chain; Diuretics; Glucagon; Hepatic Encephalopathy; Humans; Insulin; Jaundice; Lactulose; Liver Cirrhosis | 1994 |
[Lactulose fermentation and lactose absorption in Chilean patients with liver cirrhosis: importance for hepatic encephalopathy therapy].
Topics: Adolescent; Adult; Aged; Case-Control Studies; Child; Chile; Female; Fermentation; Hepatic Encephalopathy; Humans; Hydrogen; Lactose Intolerance; Lactulose; Liver Cirrhosis; Male; Middle Aged | 1993 |
Prevalence of latent portasystemic encephalopathy in an unselected population of patients with liver cirrhosis in general practice.
Topics: Adult; Aged; Cross-Sectional Studies; Drug Monitoring; Family Practice; Female; Germany; Hepatic Encephalopathy; Humans; Hypertension, Portal; Incidence; Lactulose; Liver Cirrhosis; Male; Middle Aged; Neuropsychological Tests; Psychometrics | 1993 |
[Enteral detoxication in patients with liver cirrhosis and bleeding from the esophageal and gastric varices ].
Topics: Combined Modality Therapy; Embolization, Therapeutic; Endoscopy, Digestive System; Esophageal and Gastric Varices; Gastric Lavage; Gastrointestinal Agents; Humans; Lactulose; Liver Cirrhosis; Recurrence; Sorption Detoxification; Treatment Outcome; Urea | 1997 |
Prevalence and clinical importance of hypertransaminasaemia in coeliac disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Aspartate Aminotransferases; Biopsy; Celiac Disease; Diet, Protein-Restricted; Dietary Proteins; Diuretics, Osmotic; Female; Follow-Up Studies; Gastrointestinal Agents; Glutens; Hepatitis; Humans; Intestine, Small; Lactulose; Liver; Liver Cirrhosis; Male; Mannitol; Middle Aged; Permeability; Prevalence; Retrospective Studies | 1999 |
Helicobacter pylori infection, plasma ammonia levels, and psychometric testing in cirrhotic patients.
Topics: Adult; Aged; Ammonia; Female; Helicobacter Infections; Helicobacter pylori; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Neuropsychological Tests; Psychometrics | 1999 |
Intestinal permeability in liver cirrhosis: relationship with severe septic complications.
Topics: Bacteremia; Bacterial Translocation; Cell Membrane Permeability; Female; Humans; Intestinal Absorption; Intestines; Lactulose; Liver Cirrhosis; Male; Mannitol; Middle Aged; Peritonitis | 1999 |
[Chronic liver diseases. Hepatic encephalopathy too frequently overlooked?].
Topics: Ammonia; Dipeptides; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Neomycin | 2000 |
Hepatic Encephalopathy.
Topics: Adult; Bromocriptine; Dietary Proteins; Digestive System; Flumazenil; Gastrointestinal Agents; Goals; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Neurotransmitter Agents; Nitrogen; Splanchnic Circulation; Therapeutic Irrigation | 2001 |
Lactulose-induced pneumatosis intestinalis and pneumoperitoneum.
Topics: Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Pneumatosis Cystoides Intestinalis; Pneumoperitoneum | 2001 |
[Different therapeutic approaches for chronic diffuse liver lesions using ornicetil, lactulose, etimizol and corinfar].
Topics: Etimizol; Hepatic Encephalopathy; Hepatitis, Chronic; Humans; Lactulose; Liver Cirrhosis; Liver Diseases; Middle Aged; Nifedipine; Ornithine; Treatment Outcome | 2002 |
Emergency treatment of portal-systemic encephalopathy with lactulose enemas. A controlled study.
Topics: Ammonia; Disaccharides; Emergencies; Enema; Female; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male | 1979 |
Control of endotoxinemia in liver disease by lactulose and paromomycin.
Topics: Chronic Disease; Disaccharides; Endotoxins; Hepatitis; Hepatitis B; Humans; Lactulose; Limulus Test; Liver Cirrhosis; Liver Diseases; Paromomycin | 1979 |
The liver: a pharmacologic perspective.
Topics: Acetaldehyde; Alcoholism; Chemical and Drug Induced Liver Injury; Diuretics; Drug-Related Side Effects and Adverse Reactions; Ethanol; Hepatic Encephalopathy; Humans; Inactivation, Metabolic; Lactulose; Levodopa; Liver; Liver Cirrhosis; Liver Diseases; Microsomes, Liver; Neomycin; Oxidation-Reduction; Pharmaceutical Preparations; Spironolactone; Vasopressins | 1977 |
[Present-day therapy of hepatic encephalopathy (author's transl)].
Topics: Acid-Base Imbalance; Ammonia; Anemia; Anti-Bacterial Agents; Exchange Transfusion, Whole Blood; Glucose; Hepatic Encephalopathy; Humans; Hypoxia; Intestinal Mucosa; Ketoglutaric Acids; Kidney; Lactulose; Liver Cirrhosis; Ornithine; Perfusion; Prognosis; Renal Dialysis | 1976 |
[Conservative therapy of liver cirrhosis].
Topics: Anabolic Agents; Diet, Sodium-Restricted; Humans; Lactulose; Liver Cirrhosis; Neomycin; Prednisolone | 1977 |
[Clinical picture and therapy of portal-systemic encephalopathy (author's transl)].
Topics: Acetates; Acidosis; Alcoholism; Amino Acids; Ammonia; Astrocytes; Dietary Proteins; Diuretics; Hemorrhage; Hepatic Encephalopathy; Humans; Hypokalemia; Lactulose; Liver; Liver Cirrhosis; Neomycin; Potassium; Skin Manifestations; Water-Electrolyte Balance | 1977 |
[Treatment of cirrhotic encephalopathy].
Topics: Amino Acids; Anti-Bacterial Agents; Dietary Proteins; Disaccharides; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis | 1976 |
[Hyperammoniemia and porta-caval encephalopathy in patients with cirrhosis. Personal results of lactulose treatment].
Topics: Adult; Aged; Ammonia; Disaccharides; Female; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Portacaval Shunt, Surgical | 1975 |
[Therapy of coma in liver cirrhosis].
Topics: Adenosine Triphosphate; Ammonia; Arginine; Brain; Colon; Disaccharides; Hepatic Encephalopathy; Humans; Hydroxamic Acids; Intestinal Absorption; Lactulose; Levodopa; Liver Cirrhosis | 1975 |
[Portal hypertension from the internal medicine viewpoint].
Topics: Furosemide; Humans; Hypertension, Portal; Lactulose; Liver Cirrhosis; Spironolactone; Vasopressins | 1976 |
Malabsorption and nutritional abnormalities in patients with liver cirrhosis.
Topics: 3-O-Methylglucose; Adult; Aged; alpha 1-Antitrypsin; Celiac Disease; Feces; Female; Humans; Intestinal Absorption; Lactulose; Lipids; Liver Cirrhosis; Malabsorption Syndromes; Male; Methylglucosides; Middle Aged; Nutrition Disorders; Nutritional Status; Rhamnose; Skinfold Thickness; Weight Loss; Xylose | 1990 |
[Therapeutic effect of vancomycin hydrochloride, a nonabsorbable antibiotic, on intractable (lactulose resistant) chronic hepatic encephalopathy in cirrhotic patients].
Topics: Aged; Chronic Disease; Drug Resistance; Female; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Male; Middle Aged; Vancomycin | 1986 |
[Treatment of patients with chronic liver diseases with lactulose and bifidum milk. Principles and problems].
Topics: Biological Products; Disaccharides; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis | 1988 |
Investigation of intestine and liver function in cirrhosis using combined sugar oral loads.
Topics: Adult; Aged; Female; Humans; Intestinal Absorption; Intestinal Mucosa; Lactulose; Liver; Liver Cirrhosis; Male; Methylglucosides; Middle Aged; Rhamnose; Xylose | 1985 |
[Ambulatory diagnosis and therapy control of portasystemic encephalopathy in patients with liver cirrhosis].
Topics: Aged; Ammonia; Female; Hepatic Encephalopathy; Humans; Hypertension, Portal; Lactulose; Liver Cirrhosis; Male; Middle Aged; Neomycin; Neuropsychological Tests; Psychomotor Performance; Reaction Time; Tremor | 1985 |
[Intestine and liver-protective therapy].
Topics: Diabetes Mellitus; Disaccharides; Dyspepsia; Gastrointestinal Motility; Humans; Lactobacillus; Lactulose; Liver Cirrhosis; Liver Diseases | 1974 |
[Lactulose in the treatment of chronic portosystemic encephalopathies].
Topics: Adult; Aged; Chronic Disease; Disaccharides; Electroencephalography; Female; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Liver Diseases; Male; Mental Disorders; Middle Aged; Nervous System Diseases | 1974 |
Comparative study of basal arterial ammonemia and of orally-induced hyperammonemia in chronic portal systemic encephalopathy, treated with neomycin, lactulose, and an association of neomycin and lactulose.
Topics: Ammonia; Blood Urea Nitrogen; Brain Diseases; Chlorides; Chronic Disease; Disaccharides; Drug Therapy, Combination; Hepatic Encephalopathy; Humans; Hydrogen-Ion Concentration; Lactulose; Liver Cirrhosis; Liver Function Tests; Neomycin; Potassium; Sodium | 1974 |
[Correction by L-dopa of neurologic manifestations of a chronic portocaval encephalopathy].
Topics: Alcoholism; Ammonia; Brain Diseases; Dihydroxyphenylalanine; Electroencephalography; Humans; Ketoglutaric Acids; Lactulose; Liver Cirrhosis; Male; Middle Aged; Neurologic Manifestations; Ornithine; Prednisone; Silicosis; Tremor | 1972 |
Lactulose in the treatment of acute hepatic encephalopathy.
Topics: Acute Disease; Ammonia; Connecticut; Dietary Proteins; Evaluation Studies as Topic; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Neomycin; Nitrogen | 1973 |
[Lactulose in the therapy of porto-systemic encephalopathy].
Topics: Adult; Aged; Brain Diseases; Disaccharides; Hepatic Encephalopathy; Humans; Lactulose; Liver Cirrhosis; Middle Aged | 1973 |